Survey of Adults in South Korea with Urothelial Cancer Receiving PADCEV Injection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on adults in South Korea diagnosed with locally advanced or metastatic urothelial cancer who are receiving PADCEV Injection as part of their standard treatment. The study aims to collect data on treatment outcomes and any medical issues that arise during the observation period, which lasts up to 48 weeks after the first dose of PADCEV. Participants will be monitored through their medical records to assess the effectiveness and safety of the treatment in a real-world setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who receive treatment with PADCEV Injection, according to the approved local label.

Exclusion Criteria:

* Patients with any contraindication for PADCEV Injection, according to the approved local label.
* Patients who receive or are going to receive any investigational medicine during the observation period.

Where it's running

• Site KR82001
  Goyang-si, Gyeonggi-do, South Korea Recruiting
• Site KR82012
  Suwon, Gyeonggi-do, South Korea Recruiting
• Site KR82008
  Suwon, Gyeonggi-do, South Korea Recruiting
• Site KR82007
  Jeollanam-do, Jeollanam-do, South Korea Recruiting
• Site KR82013
  Jeonju, Jeonbuk-do, South Korea Recruiting
• Site KR82010
  Busan, South Korea Recruiting

Study contacts

• Study coordinator: Astellas Pharma Global Development, Inc.
• Email: astellas.registration@astellas.com
• Phone: 800-888-7704

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Peripheral neuropathy during perioperative therapy with enfortumab vedotin and pembrolizumab in muscle-invasive urothelial cancer

  This study follows adults with muscle-invasive urothelial cancer to see how nerve-related side effects develop when people receive enfortumab vedotin and pembrolizumab around surgery as part of standard care.

  Recruiting at 3 sites Comprehensive Cancer Center Munich (CCCM) · Munich, Bavaria and 2 other locations · NCT07870577

• Enfortumab vedotin plus pembrolizumab versus chemoradiotherapy for muscle-invasive bladder cancer

  This trial tests whether combining enfortumab vedotin with pembrolizumab can help people with non-metastatic muscle-invasive bladder cancer keep their bladder and control the cancer better than standard concurrent chemoradiotherapy.

  Recruiting at 29 sites Phase 3 Astellas Pharma Inc · Little Rock, Arkansas and 28 other locations · NCT07566156

• PF-08634404 alone or with enfortumab vedotin for advanced urothelial (bladder) cancer

  This trial will try PF-08634404 by itself or together with enfortumab vedotin to see if it is safe and helps adults with advanced or metastatic urothelial (bladder) cancer.

  Recruiting at 173 sites Phase 1/2 Pfizer · Fayetteville, Arkansas and 183 other locations · NCT07421700

• Investigating nerve damage in patients treated for advanced bladder cancer

  This study is testing how the treatments enfortumab vedotin and pembrolizumab affect nerve damage and quality of life in people with advanced bladder cancer.

  Recruiting at 4 sites Comprehensive Cancer Center Munich (CCCM) · Augsburg, Bavaria and 3 other locations · NCT06657157

• Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial cancer

  This trial tests whether combining sacituzumab govitecan and enfortumab vedotin, with pembrolizumab in some patients, helps people with metastatic urothelial carcinoma who have progressed after platinum chemotherapy and PD‑1/PD‑L1 inhibitors.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04724018

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.